デフォルト表紙
市場調査レポート
商品コード
992688

血液製剤の世界市場

Blood Preparation

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 372 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.86円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

血液製剤の世界市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 372 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の血液製剤の市場規模は、分析期間(2020年~2027年)に5.3%のCAGRで成長する見通しで、2020年の393億米ドルから、2027年には566億米ドルに達すると予測されています。

当レポートで分析されているセグメントの1つである全血は、分析期間中に5.1%のCAGRで成長し、253億米ドルに達すると予測されています。

当レポートは、世界の血液製剤市場について調査しており、市場シェア、Covid-19の影響、動向や成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

調査対象企業の例

  • AstraZeneca plc
  • Baxter International Inc
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • Leo Pharma A/S
  • Pfizer, Inc
  • Sanofi
  • Xiamen Hisunny Chemical Co., LTD

目次

I. 調査手法

II. エグゼクティブサマリー

  • 市場概要
    • インフルエンサー市場の洞察
    • 世界市場の軌跡
    • Covid-19の影響と迫り来る世界の景気後退
  • 主要企業
  • 動向と推進要因
  • 世界市場の見通し

III. 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

IV. 競合

  • 企業プロファイル:33社
目次
Product Code: MCP21370

Abstract:

Global Blood Preparation Market to Reach $56.6 Billion by 2027

Amid the COVID-19 crisis, the global market for Blood Preparation estimated at US$39.3 Billion in the year 2020, is projected to reach a revised size of US$56.6 Billion by 2027, growing at a CAGR of 5.3% over the analysis period 2020-2027. Whole Blood, one of the segments analyzed in the report, is projected to record a 5.1% CAGR and reach US$25.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Blood Components segment is readjusted to a revised 5.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $10.6 Billion, While China is Forecast to Grow at 8.6% CAGR

The Blood Preparation market in the U.S. is estimated at US$10.6 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$12.1 Billion by the year 2027 trailing a CAGR of 8.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Blood Derivatives Segment to Record 5.7% CAGR

In the global Blood Derivatives segment, USA, Canada, Japan, China and Europe will drive the 5.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$6.2 Billion in the year 2020 will reach a projected size of US$8.9 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$7.7 Billion by the year 2027, while Latin America will expand at a 6.1% CAGR through the analysis period.

Select Competitors (Total 33 Featured) -

  • AstraZeneca plc
  • Baxter International Inc
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • Leo Pharma A/S
  • Pfizer, Inc
  • Sanofi
  • Xiamen Hisunny Chemical Co., LTD

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Blood Preparation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Blood Preparation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Blood Preparation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Whole Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Whole Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Whole Blood by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Blood Components by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Blood Components by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Blood Components by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Blood Derivatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Blood Derivatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Blood Derivatives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Renal Impairment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Renal Impairment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Renal Impairment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Thrombocytosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Thrombocytosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Thrombocytosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Pulmonary Embolism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Pulmonary Embolism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Pulmonary Embolism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Angina Blood Vessel Complications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Angina Blood Vessel Complications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Angina Blood Vessel Complications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Platelet Aggregation Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Platelet Aggregation Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Platelet Aggregation Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 34: World Current & Future Analysis for Fibrinolytics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 35: World Historic Review for Fibrinolytics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: World 15-Year Perspective for Fibrinolytics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 37: USA Current & Future Analysis for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: USA Historic Review for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: USA 15-Year Perspective for Blood Preparation by Product - Percentage Breakdown of Value Sales for Whole Blood, Blood Components and Blood Derivatives for the Years 2012, 2020 & 2027
    • TABLE 40: USA Current & Future Analysis for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: USA Historic Review for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: USA 15-Year Perspective for Blood Preparation by Application - Percentage Breakdown of Value Sales for Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications for the Years 2012, 2020 & 2027
    • TABLE 43: USA Current & Future Analysis for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: USA Historic Review for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: USA 15-Year Perspective for Blood Preparation by Type - Percentage Breakdown of Value Sales for Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 46: Rest of Europe Current & Future Analysis for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Rest of Europe Historic Review for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Rest of Europe 15-Year Perspective for Blood Preparation by Product - Percentage Breakdown of Value Sales for Whole Blood, Blood Components and Blood Derivatives for the Years 2012, 2020 & 2027
    • TABLE 49: Rest of Europe Current & Future Analysis for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Rest of Europe Historic Review for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Rest of Europe 15-Year Perspective for Blood Preparation by Application - Percentage Breakdown of Value Sales for Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications for the Years 2012, 2020 & 2027
    • TABLE 52: Rest of Europe Current & Future Analysis for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Rest of Europe Historic Review for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Rest of Europe 15-Year Perspective for Blood Preparation by Type - Percentage Breakdown of Value Sales for Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 55: Australia Current & Future Analysis for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Australia Historic Review for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Australia 15-Year Perspective for Blood Preparation by Product - Percentage Breakdown of Value Sales for Whole Blood, Blood Components and Blood Derivatives for the Years 2012, 2020 & 2027
    • TABLE 58: Australia Current & Future Analysis for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Australia Historic Review for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Australia 15-Year Perspective for Blood Preparation by Application - Percentage Breakdown of Value Sales for Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications for the Years 2012, 2020 & 2027
    • TABLE 61: Australia Current & Future Analysis for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Australia Historic Review for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Australia 15-Year Perspective for Blood Preparation by Type - Percentage Breakdown of Value Sales for Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 64: India Current & Future Analysis for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: India Historic Review for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: India 15-Year Perspective for Blood Preparation by Product - Percentage Breakdown of Value Sales for Whole Blood, Blood Components and Blood Derivatives for the Years 2012, 2020 & 2027
    • TABLE 67: India Current & Future Analysis for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: India Historic Review for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: India 15-Year Perspective for Blood Preparation by Application - Percentage Breakdown of Value Sales for Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications for the Years 2012, 2020 & 2027
    • TABLE 70: India Current & Future Analysis for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: India Historic Review for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: India 15-Year Perspective for Blood Preparation by Type - Percentage Breakdown of Value Sales for Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 73: South Korea Current & Future Analysis for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: South Korea Historic Review for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: South Korea 15-Year Perspective for Blood Preparation by Product - Percentage Breakdown of Value Sales for Whole Blood, Blood Components and Blood Derivatives for the Years 2012, 2020 & 2027
    • TABLE 76: South Korea Current & Future Analysis for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: South Korea Historic Review for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: South Korea 15-Year Perspective for Blood Preparation by Application - Percentage Breakdown of Value Sales for Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications for the Years 2012, 2020 & 2027
    • TABLE 79: South Korea Current & Future Analysis for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: South Korea Historic Review for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: South Korea 15-Year Perspective for Blood Preparation by Type - Percentage Breakdown of Value Sales for Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 82: Rest of Asia-Pacific Current & Future Analysis for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Rest of Asia-Pacific Historic Review for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Rest of Asia-Pacific 15-Year Perspective for Blood Preparation by Product - Percentage Breakdown of Value Sales for Whole Blood, Blood Components and Blood Derivatives for the Years 2012, 2020 & 2027
    • TABLE 85: Rest of Asia-Pacific Current & Future Analysis for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Rest of Asia-Pacific Historic Review for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Rest of Asia-Pacific 15-Year Perspective for Blood Preparation by Application - Percentage Breakdown of Value Sales for Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications for the Years 2012, 2020 & 2027
    • TABLE 88: Rest of Asia-Pacific Current & Future Analysis for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Rest of Asia-Pacific Historic Review for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Rest of Asia-Pacific 15-Year Perspective for Blood Preparation by Type - Percentage Breakdown of Value Sales for Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 91: Argentina Current & Future Analysis for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Argentina Historic Review for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Argentina 15-Year Perspective for Blood Preparation by Product - Percentage Breakdown of Value Sales for Whole Blood, Blood Components and Blood Derivatives for the Years 2012, 2020 & 2027
    • TABLE 94: Argentina Current & Future Analysis for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Argentina Historic Review for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Argentina 15-Year Perspective for Blood Preparation by Application - Percentage Breakdown of Value Sales for Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications for the Years 2012, 2020 & 2027
    • TABLE 97: Argentina Current & Future Analysis for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Argentina Historic Review for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Argentina 15-Year Perspective for Blood Preparation by Type - Percentage Breakdown of Value Sales for Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 100: Brazil Current & Future Analysis for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Brazil Historic Review for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Brazil 15-Year Perspective for Blood Preparation by Product - Percentage Breakdown of Value Sales for Whole Blood, Blood Components and Blood Derivatives for the Years 2012, 2020 & 2027
    • TABLE 103: Brazil Current & Future Analysis for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Brazil Historic Review for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Brazil 15-Year Perspective for Blood Preparation by Application - Percentage Breakdown of Value Sales for Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications for the Years 2012, 2020 & 2027
    • TABLE 106: Brazil Current & Future Analysis for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Brazil Historic Review for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Brazil 15-Year Perspective for Blood Preparation by Type - Percentage Breakdown of Value Sales for Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 109: Mexico Current & Future Analysis for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Mexico Historic Review for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: Mexico 15-Year Perspective for Blood Preparation by Product - Percentage Breakdown of Value Sales for Whole Blood, Blood Components and Blood Derivatives for the Years 2012, 2020 & 2027
    • TABLE 112: Mexico Current & Future Analysis for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Mexico Historic Review for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: Mexico 15-Year Perspective for Blood Preparation by Application - Percentage Breakdown of Value Sales for Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications for the Years 2012, 2020 & 2027
    • TABLE 115: Mexico Current & Future Analysis for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Mexico Historic Review for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: Mexico 15-Year Perspective for Blood Preparation by Type - Percentage Breakdown of Value Sales for Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 118: Rest of Latin America Current & Future Analysis for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Rest of Latin America Historic Review for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: Rest of Latin America 15-Year Perspective for Blood Preparation by Product - Percentage Breakdown of Value Sales for Whole Blood, Blood Components and Blood Derivatives for the Years 2012, 2020 & 2027
    • TABLE 121: Rest of Latin America Current & Future Analysis for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Rest of Latin America Historic Review for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 123: Rest of Latin America 15-Year Perspective for Blood Preparation by Application - Percentage Breakdown of Value Sales for Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications for the Years 2012, 2020 & 2027
    • TABLE 124: Rest of Latin America Current & Future Analysis for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Rest of Latin America Historic Review for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 126: Rest of Latin America 15-Year Perspective for Blood Preparation by Type - Percentage Breakdown of Value Sales for Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 127: Iran Current & Future Analysis for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Iran Historic Review for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 129: Iran 15-Year Perspective for Blood Preparation by Product - Percentage Breakdown of Value Sales for Whole Blood, Blood Components and Blood Derivatives for the Years 2012, 2020 & 2027
    • TABLE 130: Iran Current & Future Analysis for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Iran Historic Review for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 132: Iran 15-Year Perspective for Blood Preparation by Application - Percentage Breakdown of Value Sales for Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications for the Years 2012, 2020 & 2027
    • TABLE 133: Iran Current & Future Analysis for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Iran Historic Review for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 135: Iran 15-Year Perspective for Blood Preparation by Type - Percentage Breakdown of Value Sales for Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 136: Israel Current & Future Analysis for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Israel Historic Review for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 138: Israel 15-Year Perspective for Blood Preparation by Product - Percentage Breakdown of Value Sales for Whole Blood, Blood Components and Blood Derivatives for the Years 2012, 2020 & 2027
    • TABLE 139: Israel Current & Future Analysis for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Israel Historic Review for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 141: Israel 15-Year Perspective for Blood Preparation by Application - Percentage Breakdown of Value Sales for Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications for the Years 2012, 2020 & 2027
    • TABLE 142: Israel Current & Future Analysis for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Israel Historic Review for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 144: Israel 15-Year Perspective for Blood Preparation by Type - Percentage Breakdown of Value Sales for Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 145: Saudi Arabia Current & Future Analysis for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Saudi Arabia Historic Review for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 147: Saudi Arabia 15-Year Perspective for Blood Preparation by Product - Percentage Breakdown of Value Sales for Whole Blood, Blood Components and Blood Derivatives for the Years 2012, 2020 & 2027
    • TABLE 148: Saudi Arabia Current & Future Analysis for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Saudi Arabia Historic Review for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 150: Saudi Arabia 15-Year Perspective for Blood Preparation by Application - Percentage Breakdown of Value Sales for Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications for the Years 2012, 2020 & 2027
    • TABLE 151: Saudi Arabia Current & Future Analysis for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Saudi Arabia Historic Review for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 153: Saudi Arabia 15-Year Perspective for Blood Preparation by Type - Percentage Breakdown of Value Sales for Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 154: UAE Current & Future Analysis for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 155: UAE Historic Review for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 156: UAE 15-Year Perspective for Blood Preparation by Product - Percentage Breakdown of Value Sales for Whole Blood, Blood Components and Blood Derivatives for the Years 2012, 2020 & 2027
    • TABLE 157: UAE Current & Future Analysis for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 158: UAE Historic Review for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 159: UAE 15-Year Perspective for Blood Preparation by Application - Percentage Breakdown of Value Sales for Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications for the Years 2012, 2020 & 2027
    • TABLE 160: UAE Current & Future Analysis for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 161: UAE Historic Review for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 162: UAE 15-Year Perspective for Blood Preparation by Type - Percentage Breakdown of Value Sales for Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 163: Rest of Middle East Current & Future Analysis for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Rest of Middle East Historic Review for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 165: Rest of Middle East 15-Year Perspective for Blood Preparation by Product - Percentage Breakdown of Value Sales for Whole Blood, Blood Components and Blood Derivatives for the Years 2012, 2020 & 2027
    • TABLE 166: Rest of Middle East Current & Future Analysis for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Rest of Middle East Historic Review for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 168: Rest of Middle East 15-Year Perspective for Blood Preparation by Application - Percentage Breakdown of Value Sales for Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications for the Years 2012, 2020 & 2027
    • TABLE 169: Rest of Middle East Current & Future Analysis for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Rest of Middle East Historic Review for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 171: Rest of Middle East 15-Year Perspective for Blood Preparation by Type - Percentage Breakdown of Value Sales for Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 172: Africa Current & Future Analysis for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Africa Historic Review for Blood Preparation by Product - Whole Blood, Blood Components and Blood Derivatives Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 174: Africa 15-Year Perspective for Blood Preparation by Product - Percentage Breakdown of Value Sales for Whole Blood, Blood Components and Blood Derivatives for the Years 2012, 2020 & 2027
    • TABLE 175: Africa Current & Future Analysis for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Africa Historic Review for Blood Preparation by Application - Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 177: Africa 15-Year Perspective for Blood Preparation by Application - Percentage Breakdown of Value Sales for Renal Impairment, Other Applications, Thrombocytosis, Pulmonary Embolism and Angina Blood Vessel Complications for the Years 2012, 2020 & 2027
    • TABLE 178: Africa Current & Future Analysis for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Africa Historic Review for Blood Preparation by Type - Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 180: Africa 15-Year Perspective for Blood Preparation by Type - Percentage Breakdown of Value Sales for Anticoagulants, Platelet Aggregation Inhibitors and Fibrinolytics for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 33